Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026. The subcutaneous formulation of the drug VK2735 is ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Eli Lilly and Company LLY reported second-quarter 2025 adjusted earnings per share (“EPS”) of $6.31, which beat the Zacks Consensus Estimate of $5.61 per share. Earnings rose 61% year over year.
Shares of Rhythm PharmaceuticalsRYTM wavered Tuesday after the biotech's experimental weight-loss drug missed its mark in a yearlong study. The company hoped to show targeting gene variants along the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 13% year over year as higher revenues were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results